Literature DB >> 21448568

Lack of the serotonin transporter (SERT) reduces the ability of 5-hydroxytryptamine to lower blood pressure.

Robert Patrick Davis1, A Elizabeth Linder, Stephanie W Watts.   

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) is a potent constrictor of isolated blood vessels. However, recent studies demonstrate that chronic 5-HT infusion results in a prolonged fall in blood pressure in the rat. This finding highlights the need for further study of 5-HT in the cardiovascular system. We tested the hypothesis that a functional serotonin transporter (SERT) is critical to enabling a 5-HT-induced fall in blood pressure. Experiments were performed in male and female rats to determine whether gender significantly affected the ability of 5-HT to lower blood pressure and to determine whether SERT dependence was different in male vs. female rats. 5-HT (25 μg/kg/min; s.c.) was infused for 7 days to male and female, SERT wild-type (WT) and SERT knockout (KO) rats. Mean arterial pressure (MAP) and heart rate were monitored via radiotelemetry. 5-HT produced a significantly greater fall in MAP (at the nadir) in the male SERT WT rat (-20 ± 1 mmHg) compared to the male SERT KO rat (-10 ± 2 mmHg). Similarly, 5-HT also produced a significantly greater fall in MAP (at the nadir) in the female SERT WT rat (-19 ± 1 mmHg) compared to the female SERT KO rat (-15 ± 0.4 mmHg). While the lack of a functional SERT protein did not prevent a 5-HT-induced fall in blood pressure, it did reduce the ability of 5-HT to lower blood pressure in the male and female SERT rat, suggesting a potentially important role for SERT in producing a 5-HT-induced fall in blood pressure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448568      PMCID: PMC3097417          DOI: 10.1007/s00210-011-0622-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

1.  Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine.

Authors:  V ERSPAMER; B ASERO
Journal:  Nature       Date:  1952-05-10       Impact factor: 49.962

2.  Serum vasoconstrictor, serotonin; isolation and characterization.

Authors:  M M RAPPORT; A A GREEN; I H PAGE
Journal:  J Biol Chem       Date:  1948-12       Impact factor: 5.157

3.  Impaired uptake of 5 hydroxytryptamine platelet in essential hypertension: clinical relevance.

Authors:  N Fetkovska; A Pletscher; F Ferracin; R Amstein; F R Buhler
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

4.  Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity.

Authors:  B Chanrion; C Mannoury la Cour; F Bertaso; M Lerner-Natoli; M Freissmuth; M J Millan; J Bockaert; P Marin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

5.  Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat.

Authors:  Yasushi Nakatani; Ikuko Sato-Suzuki; Naohisa Tsujino; Akane Nakasato; Yoshinari Seki; Masaki Fumoto; Hideho Arita
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

6.  Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system.

Authors:  J R Homberg; J D A Olivier; B M G Smits; J D Mul; J Mudde; M Verheul; O F M Nieuwenhuizen; A R Cools; E Ronken; T Cremers; A N M Schoffelmeer; B A Ellenbroek; E Cuppen
Journal:  Neuroscience       Date:  2007-04-30       Impact factor: 3.590

7.  5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats.

Authors:  Jessica Diaz; Wei Ni; Janice Thompson; Andrew King; Gregory D Fink; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2008-02-27       Impact factor: 4.030

8.  A serotonergic system in veins: serotonin transporter-independent uptake.

Authors:  A Elizabeth Linder; Wei Ni; Theodora Szasz; Robert Burnett; Jessica Diaz; Timothy J Geddes; Donald M Kuhn; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2008-03-05       Impact factor: 4.030

9.  Plasma serotonin levels and the platelet serotonin transporter.

Authors:  B Brenner; J T Harney; B A Ahmed; B C Jeffus; R Unal; J L Mehta; F Kilic
Journal:  J Neurochem       Date:  2007-05-15       Impact factor: 5.372

10.  The serotonin transporter is present and functional in peripheral arterial smooth muscle.

Authors:  Wei Ni; Janice M Thompson; Carrie A Northcott; Keith Lookingland; Stephanie W Watts
Journal:  J Cardiovasc Pharmacol       Date:  2004-06       Impact factor: 3.105

View more
  6 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  5-HT causes splanchnic venodilation.

Authors:  Bridget M Seitz; Hakan S Orer; Teresa Krieger-Burke; Emma S Darios; Janice M Thompson; Gregory D Fink; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

3.  5-Hydroxytryptamine does not reduce sympathetic nerve activity or neuroeffector function in the splanchnic circulation.

Authors:  Emma S Darios; Susan M Barman; Hakan S Orer; Shaun F Morrison; Robert P Davis; Bridget M Seitz; Robert Burnett; Stephanie W Watts
Journal:  Eur J Pharmacol       Date:  2015-02-28       Impact factor: 4.432

Review 4.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

5.  One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat.

Authors:  Robert Patrick Davis; Theodora Szasz; Hannah Garver; Robert Burnett; Nathan R Tykocki; Stephanie W Watts
Journal:  ACS Chem Neurosci       Date:  2012-09-16       Impact factor: 4.418

6.  5-Hydroxytryptamine Changes under Different Pretreatments on Rat Models of Myocardial Infarction and/or Depression.

Authors:  Mei-Yan Liu; Li-Jun Zhang; Yu-Xin Zhou; Wan-Lin Wei
Journal:  Chin Med J (Engl)       Date:  2017-09-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.